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Abstract
The renal status of patients with bone metastases secondary to solid tumors
and their treatment with nephrotoxic agents is not well characterized. This ret-
rospective study analyzed electronic medical records data from US-based oncol-
ogy clinics to identify adult (age ≥18) solid tumor patients with first bone
metastasis diagnosis and ≥1 serum creatinine recorded between January 1, 2009
and December 31, 2013. Patients with multiple myeloma, multiple primary
tumor types, acute renal failure, and/or end-stage renal disease were excluded.
Using the Chronic Kidney Disease Epidemiology Collaboration formula, we
determined the prevalence of renal impairment (RI: single estimated glomerular
filtration rate [eGFR] value <60 mL/min per 1.73 m2) and chronic kidney dis-
ease (CKD: ≥2 eGFR values <60, at least 90 days apart). We also examined the
use of intravenous bisphosphonates (IV BP) and other nephrotoxic agents.
Approximately half of the 11,809 patients were female. Breast (34%) and lung
(28%) tumors were the most common. At bone metastasis diagnosis, mean age
was 67 years and 24% of patients exhibited RI. The 5-year prevalence was 43%
for RI and 71% for CKD among RI patients. Nearly half (46%) of CKD
patients received IV BP in the 12 months following their confirming eGFR and
13% of these patients received at least one other nephrotoxic agent during that
period. This is the first US-based study to examine the prevalence of RI among
patients with bone metastases from solid tumors. RI is common at bone metas-
tases diagnosis, and a substantial proportion of patients develop RI or CKD as
their disease progresses. Whenever possible, treatments that are potentially less
damaging for the kidney should be considered for patients with or predisposed
to RI.
Introduction
There is growing interest in the intersection between kid-
ney disease and cancer, with some professional organiza-
tions, such as the American Society of Nephrology as well
as the Cancer and the Kidney International Network (C-
KIN), even exploring the development of an “onconeph-
rology” subspecialty [1, 2]. The relationship between
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kidney disease and cancer is complex. Chronic kidney dis-
ease (CKD) is associated with an increased risk of some
cancers, and cancer itself can contribute to the develop-
ment of CKD or acute kidney injury [1, 3]. Furthermore,
the presence of CKD is associated with an increased risk
of death among patients with cancer, and many agents
used for the treatment of cancer (or complications from
cancer, e.g., antibiotics, antifungals) are potentially neph-
rotoxic [1, 3–15].
Patients with cancer complicated by bone metastases
may be particularly at risk for renal impairment (RI) or
CKD [16, 17]. Pamidronic and zoledronic acids are intra-
venously administered bisphosphonates (IV BP) that are
commonly used to prevent bone complications in these
patients. While these agents offer therapeutic benefit, they
are also associated with deterioration of renal function,
which limits or, at a minimum complicates, treatment
choices in individuals concurrently treated with other
nephrotoxic agents (e.g., chemotherapy) or otherwise pre-
disposed to RI [16, 17].
The renal status of patients with bone metastases sec-
ondary to solid tumors, and use of nephrotoxic agents
among these patients has not been well characterized.
We, therefore, estimated the prevalence of RI in US
patients with bone metastases secondary to solid tumors.
Electronic medical records (EMR) data from oncology
clinics were critical for the conduct of this study since
EMR capture results from laboratory studies (i.e., serum
creatinine values) that are routinely ordered in that set-
ting. In addition, these EMR allowed us to examine use
of nephrotoxic agents, including IV BP, in patients with
evidence of RI.
Methodology
This study was conducted with EMR data housed in the
Oncology Services Comprehensive Electronic Records
(OSCER) database. OSCER includes outpatient data for a
representative sample of more than 569,000 cancer
patients treated at 565 community and hospital-affiliated
oncology clinics from 2004 forward. Patients reside in all
50 states and all payer types are represented (commercial,
Medicare, Medicaid, self-pay, and other). Patient records
in OSCER are deidentified and fully compliant with the
Health Insurance Portability and Accountability Act (HI-
PAA) of 1996.
During each oncology clinic visit, detailed data includ-
ing ICD-9-CM (International Classification of Diseases
Classification 9th Revision Clinical Modification) diagno-
sis codes, CPT-4 (current procedural terminology) proce-
dure codes, laboratory test results, and treatments
administered or prescribed are captured, along with the
relevant service dates, in the EMR. Laboratory test dates,
results, applicable units and normal reference ranges are
typically entered directly into the EMR.
For this study, we identified adult (age ≥18) solid
tumor patients with a first diagnosis of bone metastasis
and at least one serum creatinine recorded between 1
January 2009 and 31 December 2013. Patients with ICD-
9-CM diagnosis codes for multiple myeloma, multiple
primary tumor types, acute renal failure, and/or end stage
renal disease on or before their first bone metastasis diag-
nosis were excluded.
The Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) formula was used to compute the esti-
mated glomerular filtration rate (eGFR) from serum
creatinine values recorded in the EMR [18]. Race is a
required input for this formula and was defaulted to Cau-
casian when missing or unknown (19% of the popula-
tion). The strict definition of CKD requires a reduced
GFR for at least 3 months. Therefore, the term “renal
impairment” is used if a patient had only a single occur-
rence of eGFR <60 mL/min per 1.73 m2. CKD is used for
patients with at least two eGFR values <60 mL/min per
1.73 m2 measured at least 90 days apart. Lists of nephro-
toxic agents (including IV BP, chemotherapy, biologic
therapy, and targeted therapy) and anticancer agents were
predefined based on literature review and expert clinical
consultation. Results are reported overall, and in some
cases by tumor type: breast, prostate, lung, renal or other.
The demographic and clinical characteristics of the
study population, including mean eGFR and renal status
based on assessments in the 3 months prior to and
1 month after bone metastasis diagnosis, were summa-
rized. We estimated the prevalence of RI and of CKD in
2009–2013 for the study population overall and stratified
by tumor type. We also examined distribution of these
patients across eGFR categories: <15, 15–29, and 30–
59 mL/min per 1.73 m2. Among patients with RI, we
determined the number and proportion using any neph-
rotoxic agents, IV BP, and IV BP plus another nephro-
toxic agent in the 12 months prior to and 12 months
after the lowest recorded eGFR. Among CKD patients,
use of these agents was assessed in the 12 months prior
to and 12 months after the date of the confirming (sec-
ond) eGFR value.
Results
A total of 24,512 patients with diagnoses of solid tumors
and bone metastasis were identified. Among these
patients, 11,809 (48%) met the inclusion criteria. The cri-
terion for patients to have at least one serum creatinine
value recorded during the study period eliminated ~36%
of the patients who met the criteria applied earlier in the
selection process (Fig. 1).
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Demographic and clinical characteristics of the study
population are presented in Table 1. Females comprised
just over half of the study population (51%), and the
majority (66%) of the patients were Caucasian. On aver-
age, patients were 67 years old at the time of their bone
metastasis diagnosis.
Breast and lung cancer were the most common tumors,
accounting for 34% and 28% of the study population,
respectively. Of the 11,189 (95%) patients with a serum
creatinine assessment around the time of bone metastasis
diagnosis, the mean eGFR was 77.3 mL/min per 1.73 m2
and 24% exhibited RI (eGFRs <60 mL/min per 1.73 m2).
Approximately one-quarter (2760) of patients used a
nephrotoxic agent in the 12 months prior to the bone
metastasis diagnosis and 69% of patients used such agents
at any time thereafter. Among those using nephrotoxic
agents after their bone metastasis diagnosis, IV BP use
was observed in 6402 patients (79%). Zoledronic acid was
the most commonly used nephrotoxic agent (77%), fol-
lowed by carboplatin (31%), bevacizumab (16%), and
gemcitabine (16%) (Table S1).
RI was common among patients with bone metastases,
with 43% of patients having at least one eGFR <60 mL/
min per 1.73 m2 during the 5-year study period
(Table 2). In the majority (81%) of patients with RI, the
lowest eGFR was between 30 and 59 mL/min per
1.73 m2. IV BP use appeared to decrease after RI was
observed. Nearly half (48%) of patients with RI used IV
BP in the 12 months prior to their lowest eGFR com-
pared with 37% in the 12 months following their lowest
eGFR. This utilization pattern was observed in all three
Table 1. Characteristics of study patients (N = 11,809).
Characteristics N %
Mean age in years at time of bone
met diagnosis
66.9 NA
Mean age in years during reporting period1 67.0 NA
Female 6023 51.0
Race/ethnicity
African American 1095 9.3
Asian 78 0.7
Caucasian 7798 66.0
Hispanic 38 0.3
Other 515 4.4
Unknown/not available 2285 19.4
Tumor type
Breast 3968 33.6
Prostate 2772 23.5
Lung 3241 27.5
Other solid tumors 1828 15.5
Use of any anticancer drug within
12 months before bone metastasis diagnosis
3268 27.7
Use of any nephrotoxic drug within 12
months before bone metastasis diagnosis
2760 23.4
eGFR within 3 months prior to and 1 month
after bone metastasis diagnosis
Number of patients with eGFR 11,189 94.8
Mean eGFR 77.3
eGFR range
eGFR ≥90 3590 32.1
eGFR 60 to <90 4925 44.0
eGFR 30 to <60 2397 21.4
eGFR 15 to <30 240 2.1
eGFR <15 37 0.3
Use of any nephrotoxic drug therapy
during study period1
8140 68.9
Use of any IV BP during study period1 6402 54.2
Use of zoledronic acid during study period1 6217 52.7
Use of pamidronic acid during study period1 271 2.3
eGFR, estimated glomerular filtration rate (mL/min per 1.73 m2); IV
BP, intravenous bisphosphonate.
1On or after bone metastasis diagnosis; study period: 1 January 2009–
31 December 2013.
Figure 1. Patient selection.
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eGFR categories (<15, 15–29, 30–59), with the most
marked decrease in IV BP use (an absolute drop of 30–32
percentage points) among patients in the lowest two cate-
gories (Fig. 2).
A similar trend was observed in the use of any nephro-
toxic therapy, including IV BPs, with the percentage of
patients using these agents decreasing from 64% to 50%
after RI was detected (Table 2). As with IV BP use alone,
larger decreases in use of nephrotoxic agents were
observed among patients with the greatest levels of RI.
Approximately 70% (8247) of patients in the study
population had at least two eGFRs 90 days or more apart
Table 2. Prevalence of renal impairment and use of nephrotoxic agents.
Lowest eGFR (mL/min per 1.73 m2) in study period
<15 15–29 30–59 <60
N % N % N % N %
Patients by eGFR category1 161 1.4 794 6.7 4142 35.1 5097 43.2
Received any nephrotoxic agent(s) prior to lowest eGFR2 100 62.1 526 66.3 2642 63.8 3268 64.1
Received any nephrotoxic agent during 12 months after lowest eGFR2 41 25.5 288 36.3 2203 53.2 2532 49.7
Received both IV BP and another nephrotoxic agent during 12 months after lowest eGFR2 9 5.6 46 5.8 491 11.9 546 10.7
eGFR, estimated glomerular filtration rate; IV BP, intravenous bisphosphonate.
1Percentage of all study patients (N = 11,809).
2Percentage of all patients with at least one eGFR <60 mL/min per 1.73 m2 (N = 5097).
Figure 2. Intravenous bisphosphonates use in patients with renal impairment (N = 5097).
Table 3. Prevalence of CKD and use of nephrotoxic agents.
Confirming1 eGFR (mL/min per 1.73 m2) in study period
<15 15–29 30–59 <60
N % N % N % N %
Patients by eGFR category2 26 0.3 203 2.5 2636 32.0 2865 34.7
Received any IV BP prior to confirming eGFR3 9 34.6 80 39.4 1519 57.6 1608 56.1
Received any IV BP during 12 months after confirming eGFR3 2 7.7 39 19.2 1289 48.9 1330 46.4
Received any nephrotoxic agent prior to confirming eGFR3 11 42.3 111 54.7 1944 73.8 2066 72.1
Received any nephrotoxic agent during 12 months after confirming eGFR3 4 15.4 67 33.0 1616 61.3 1687 58.9
Received both IV BP and another nephrotoxic agent during 12 months after
confirming eGFR3
0 0.0 9 4.4 362 13.7 371 13.0
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IV BP, intravenous bisphosphonate.
1Second eGFR <60 mL/min per 1.73 m2.
2Percentage of all patients with at least two eGFR values at least 90 days apart (N = 8247).
3Percentage of all patients with CKD (N = 2865).
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(Table 3). CKD prevalence was 35% overall (76% among
patients with renal tumors; 31% to 38% among patients
with other tumor types, Table 4) and 71% among the
4258 patients with RI and two eGFRs at least 90 days
apart. Before the confirming eGFR, 56% of CKD patients
received IV BP, compared with 46% in the 12 months
afterwards (Table 3). Similarly, 72% of CKD patients
received at least one nephrotoxic agent (including IV BP)
prior to confirmation, compared with 59% of patients
afterwards. Among the 1687 patients who received any
nephrotoxic agent after CKD was confirmed, 13%
received both an IV BP and another nephrotoxic agent.
Discussion
This study is the first to examine the prevalence of RI
and use of nephrotoxic agents in patients with bone
metastases secondary to solid tumors. Based on the pres-
ence of a single eGFR <60 mL/min per 1.73 m2, a
recently recommended approach [19], ~24% (2865/
11,809) of patients in this large cohort exhibited RI
around the time of their bone metastasis diagnosis. With
this same method, the 5-year prevalence (2009–2013) of
RI was 43% among these patients with bone metastases
secondary to solid tumors. The prevalence of CKD was
35% among patients with at least two eGFRs available. IV
BP was the most commonly used nephrotoxic agent
before and after RI and CKD were detected.
In 2007, Launay-Vacher et al. published results from
the Renal Insufficiency and Anticancer Medications
(IRMA) study which was a large observational cohort
study conducted to assess the prevalence of renal insuffi-
ciency in cancer patients in France [20]. Although the
patient population (all cancer patients) and elements of
the study design (e.g., use of Cockcroft-Gault and abbre-
viated Modification of Diet in Renal Disease Improving
Global Outcomes for estimating renal insufficiency [aM-
DRD]) differ from ours, results from the IRMA study
provide some context for our findings. In IRMA’s sample
of 4685 patients from 15 oncology centers, results based
on Cockcroft-Gault and aMDRD indicated that 57% and
53% of patients had creatinine clearance (CrCL) <90 mL
per minute, and 20% and 12% had CrCL <60 mL per
minute. The majority of IRMA patients were also receiv-
ing nephrotoxic anticancer agents at the time of the
study; the most common anticancer drugs prescribed
were 5-FU, cyclophosphamide, docetaxel, epirubicin, and
gemcitabine.
The IRMA study has long served as the seminal source
of prevalence data for RI in cancer patients, despite its
relatively small sample size and narrow geographic focus.
In the time since the original publication, the IRMA data
have been further analyzed to provide estimates of renalTa
b
le
4
.
Pr
ev
al
en
ce
o
f
C
K
D
an
d
u
se
o
f
n
ep
h
ro
to
xi
c
ag
en
ts
b
y
tu
m
o
r
ty
p
e.
Tu
m
o
r
ty
p
e
B
re
as
t
(N
=
3
2
2
5
)
Pr
o
st
at
e
(N
=
2
1
3
3
)
Lu
n
g
(N
=
1
8
2
6
)
R
en
al
(N
=
1
9
0
)
O
th
er
(N
=
8
7
3
)
N
%
N
%
N
%
N
%
N
%
Pa
ti
en
ts
w
it
h
C
K
D
1
1
0
7
6
3
3
.4
8
1
1
3
8
.0
5
5
9
3
0
.6
1
4
4
7
5
.8
2
7
5
3
1
.5
R
ec
ei
ve
d
an
y
IV
B
P
p
ri
o
r
to
co
n
fi
rm
in
g
eG
FR
2
7
0
7
6
5
.7
4
1
9
5
1
.7
3
0
7
5
4
.9
5
7
3
9
.6
1
1
8
4
2
.9
R
ec
ei
ve
d
an
y
IV
B
P
d
u
ri
n
g
1
2
m
o
n
th
s
af
te
r
co
n
fi
rm
in
g
eG
FR
2
5
6
5
5
2
.5
3
6
1
4
4
.5
2
4
9
4
4
.5
4
8
3
3
.3
1
0
7
3
8
.9
R
ec
ei
ve
d
an
y
n
ep
h
ro
to
xi
c
ag
en
t
p
ri
o
r
to
co
n
fi
rm
in
g
eG
FR
2
7
9
3
7
3
.7
4
3
1
5
3
.1
5
1
1
9
1
.4
9
7
6
7
.4
2
3
4
8
5
.1
R
ec
ei
ve
d
an
y
n
ep
h
ro
to
xi
c
ag
en
t
d
u
ri
n
g
1
2
m
o
n
th
s
af
te
r
co
n
fi
rm
in
g
eG
FR
2
6
2
2
5
7
.8
3
6
6
4
5
.1
4
2
2
7
5
.5
8
3
5
7
.6
1
9
4
7
0
.6
R
ec
ei
ve
d
b
o
th
IV
B
P
an
d
an
o
th
er
n
ep
h
ro
to
xi
c
ag
en
t
d
u
ri
n
g
1
2
m
o
n
th
s
af
te
r
co
n
fi
rm
in
g
eG
FR
2
1
1
1
1
0
.3
8
1
.0
1
6
4
2
9
.3
1
9
1
3
.2
6
9
2
5
.1
C
K
D
,
ch
ro
n
ic
ki
d
n
ey
d
is
ea
se
;
eG
FR
,
es
ti
m
at
ed
g
lo
m
er
u
la
r
fi
lt
ra
ti
o
n
ra
te
;
IV
B
P,
in
tr
av
en
o
u
s
b
is
p
h
o
sp
h
o
n
at
e.
1
Pe
rc
en
ta
g
e
o
f
p
at
ie
n
ts
w
it
h
at
le
as
t
tw
o
eG
FR
va
lu
es
at
le
as
t
9
0
d
ay
s
ap
ar
t.
2
Pe
rc
en
ta
g
e
o
f
p
at
ie
n
ts
w
it
h
C
K
D
.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 717
J. Arellano et al. Renal Impairment in Bone Metastasis Patients
insufficiency in specific patient subgroups including the
elderly, and those with breast, prostate, and lung cancer
[21–24]. The Belgian Renal Insufficiency and Anticancer
Medications (BIRMA) was a similar, though smaller study
(1218 solid tumor patients from seven oncology clinics),
which has also served as a primary source of data on the
prevalence of renal insufficiency in cancer patients since
its inception in 2006 [25].
The medical landscape tends to change quickly over
time and these changes often lead to knowledge gaps and
necessitate new research. For example, since the IRMA
and BIRMA studies were completed, the Cockcroft-Gault
formula for estimating the glomerular filtration rate is no
longer routinely used, and a new formula (CKD-EPI) has
been developed. The literature notes that CKD-EPI pro-
vides a more accurate estimate of the glomerular filtration
rate than the Modification of Diet in Renal Disease equa-
tion [18]. CKD-EPI is currently more commonly used in
clinical trials, but offers an important alternative that
could replace the MDRD equation in routine clinical
practice [18, 26]. These developments presented the
opportunity to not only provide unique data on RI preva-
lence among patients with bone metastases related to
solid tumors, but the opportunity to do so using a better
estimation formula that is on the way to becoming new
the gold standard. In addition, the OSCER data were not
only more recent, but also provided a 5-year window
during which to assess prevalence, compared with the ret-
rospective data collected during two 15-day windows in
2004 for the IRMA study and from a 1-month window in
2006 for the BIRMA study. As noted earlier, the OSCER
database provided broad geographic reach within the US
and access to EMR for patients from all 50 states who
received care at one of the 565 participating oncology
clinics.
Cancer patients are at increased risk for RI; age, pre-
existing kidney disease, and chronic comorbidities (e.g.,
diabetes, hypertension, cardiac insufficiency, autoim-
mune diseases such as rheumatoid arthritis) are known
risk factors [26]. A number of commonly used cancer
therapies may also affect renal function, since these
agents are generally cleared through the kidney. These
include chemotherapy agents, molecular targeted agents,
pain medications, radiopharmaceuticals, and IV BP used
to prevent skeletal complications in patients with bone
metastases [20, 25, 26]. In the IRMA and BIRMA study
populations, between 82% and 89% of patients were
receiving an anticancer drug, the majority of which
were nephrotoxic agents [20, 25]. In our study popula-
tion, only 28% of patients received any anticancer drug
in the 12 months prior to their bone metastasis diagno-
sis, and 23% of patients received at least one nephro-
toxic agent in that period. This difference may reflect
differences in both the mix of tumor types in the study
populations (IRMA and BIRMA: 41–42% breast, 12–
13% colorectal, 8–9% lung, 6–7% ovarian/gynecologic
and 5–8% prostate) and cancer stage [20, 25]. In any
case, the percentage of patients in our study population
who received nephrotoxic therapies increased dramati-
cally from 23% to 69% following bone metastasis diag-
nosis, with the majority (79%) of those patients having
received IV BP.
Routine assessment of renal function is an important
aspect of oncology care, and such monitoring is particu-
larly important for high-risk patients including the
elderly, patients with renal tumors or predisposing co-
morbid conditions, and patients who are actively using
nephrotoxic therapies [21, 26–28]. The International Soci-
ety of Geriatric Oncology, for example, highlighted the
complexity of managing older cancer patients and noted
the importance of monitoring renal function and
responding to decreases in function by adjusting or dis-
continuing dosing of known nephrotoxic therapies,
including IV BPs [28].
Oncology care is complex and for any given patient,
treatment strategies may require making difficult trade-
offs between the potential benefits and side effects or
complications associated with both therapeutic and sup-
portive care agents. To illustrate this point, our study
indicates that 37% of patients with RI (Fig. 2) and 46%
of those with CKD (Table 2) received IV BP during the
12-months after RI was detected. In many cases, these
patients also received another nephrotoxic agent during
this same time period further increasing their risk for
worsening of their renal function.
Pamidronic and zoledronic acids were approved for
treatment of bone metastasis in 1996 and 2002, respec-
tively [29]. These IV BPs were the only agents available
for the treatment of bone metastases until 2010 when
denosumab, a fully human monoclonal antibody and
RANK Ligand inhibitor, received the US Food and
Drug Administration’s approval for use to prevent skel-
etal-related events (i.e., pathologic fractures, spinal cord
compressions, radiation to bone, bone surgery [SRE])
in patients with bone metastases secondary to solid
tumors [30, 31]. Denosumab demonstrated superiority
over zoledronic acid in preventing SRE in three large,
randomized, controlled trials [32–34]. Given that three
main antiresorptive therapies have been approved for
prevention of skeletal-related events, individual treat-
ment decisions should consider the patient’s unique
clinical situation relative to each agent’s mechanism of
action and labeled side effect profile. Considerations
include, for example, the potential for adverse effects
on renal function among patients treated with bis-
phosphonates and the potential for increased risk of
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hypocalcaemia among patients with severe renal dys-
function treated with denosumab.
Even though our results are consistent with the limited
literature on this topic, it is important to keep a few limi-
tations in mind. While the OSCER database provides
detailed clinical data for a large sample of cancer patients,
these data are generally limited to services that are pro-
vided in participating oncology/hematology clinics. Thera-
pies administered outside of these clinics would not be
captured, which may result in underestimation of nephro-
toxic agent treatment, including IV BPs. We also note
that patients who received their bone metastasis diagnosis
later in the study period had shorter follow-up, which
may also result in underestimation of use of nephrotoxic
agents and/or RI. Our reliance on the availability of
serum creatinine values collected in the course of routine
practice eliminated nearly 8000 potential patients from
the study population. This was somewhat surprising as
we would expect the majority of solid tumor patients,
especially those with bone metastases, to receive routine
renal function testing. Furthermore, this selection crite-
rion may have biased the population toward patients who
were perceived by their oncologists to be at greater risk of
renal problems, and as such may have been more likely
to undergo renal function testing. A recent study
acknowledged that this potential bias may be exacerbated
when two serum creatinine measurements are required,
and the authors concluded that a single eGFR in the out-
patient setting was sufficient to estimate CKD prevalence
[19]. To address this potential bias, we determined preva-
lence using both a single and a confirming eGFR, and
regardless of the method used, the prevalence of RI was
considerable.
In conclusion, this study provides unique data on the
prevalence of RI in patients with bone metastases second-
ary to solid tumors. In this large patient cohort, between
2009 and 2013, the prevalence of RI was 43%, and among
those with RI and multiple eGFR assessments, the preva-
lence of CKD was 71%. Despite the notable prevalence of
RI, nephrotoxic agents, including IV BPs, were commonly
used. While it is not always possible to tailor treatment
choices in light of patients’ renal status, treatments that
are potentially less damaging for the kidney should be
considered for those with or predisposed to RI.
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